Algene Holding SE, a subsidiary of DN Group AG (ISIN: DE000A3DW408), announced the successful first harvest of high-purity microalgae, marking a milestone in scaling its operations. A total yield of 4,500 litres was achieved, and the microalgae raw material is intended for particularly quality-critical products in the cosmetics and food industries, with potential applications in the pharmaceutical industry as well. The Algene platform, developed in cooperation with the Technical University of Munich, will now start series production after successful up-scaling.
Algene has already entered extensive talks with well-known companies from the cosmetics industry for the purchase of the microalgae. The initial delivery to a leading German cosmetics manufacturer is planned for the next few days, with the biomass to be used primarily for laboratory tests and validation of the active ingredients. This development comes as the market for algae as a strategic resource for food and bio-raw material grows strongly. According to the EU Commission, market growth in Europe alone is planned from 2030 to around 9 billion euros. Algae are considered an important building block of the bioeconomy.
In this rapidly growing market environment, Algene Holding is positioning itself as an industrial platform for controlled microalgae production, addressing markets such as nutrition & food, cosmetics, life sciences, and aquaculture segments. Ole Nixdorff, CEO of DN Group, stated: "For Algene, the start of series production is an important milestone. The market for microalgae is growing rapidly and offers enormous potential. The high level of interest underlines the high quality of the Algene material and the good market acceptance. As a shareholder in Algene, DN Group participates in this future market."
The news is significant because it demonstrates the commercial viability of high-purity microalgae production at scale, which could provide a sustainable source of raw materials for multiple industries. For the cosmetics and food industries, this means access to a high-quality, traceable ingredient that meets stringent purity requirements. The pharmaceutical industry may also benefit from the availability of consistent microalgae biomass for drug development. The successful series production positions Algene to capture a share of the growing bioeconomy market, which is expected to expand substantially in the coming years.
DN Group AG, which invests in impact companies with high growth opportunities in future industries such as AI, mobility, circular economy, food, health, and energy, supports Algene in this venture. The original press release can be viewed at www.newmediawire.com. For more information about DN Group, visit www.dn-ag.com.
